Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
NYSE MKT:NBY
NovaBay Pharma (NBY) Stock Price & Analysis
612 Followers
NBY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.85 - $44.80
Previous Close$2
Volume16.05K
Average Volume (3M)310.81K
Market Cap
$2.16M
Enterprise Value$1.77M
Total Cash (Recent Filing)$3.13M
Total Debt (Recent Filing)$2.74M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Aug 08, 2024EPS Estimate
-$1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-91.04
Shares Outstanding1,151,715
10 Day Avg. Volume199,673
30 Day Avg. Volume310,807
Standard Deviation0.44
R-Squared0.05
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.81
Price to Sales (P/S)0.66
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.12
Enterprise Value/Gross Profit0.22
Enterprise Value/Ebitda-0.35
Forecast
1Y Price Target
$1.68Price Target Upside-16.00% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
NovaBay Pharma News
PremiumCompany Announcements
NovaBay Pharma Outlines Strategic Future Projections
Bulls Say, Bears Say
Bulls Say
Business StrategyThe sale immediately streamlined its business and should reduce its cash burn and allows it to focus on pursuing newer and stronger growth opportunities that are better aligned with its core eyecare business.
Financial StabilityBalance sheet shows the company has enough cash to last into late 2024, enhancing its financial stability.
Market PotentialNovaBay is making good progress to market its Avenova product to the 41 million Americans who suffer from blepharitis and related eye symptoms.
Bears Say
Business SaleDERMAdoctor sales declined and the business was sold for less than its acquisition cost.
Financial PerformanceNet loss was $9.2 million, with an EPS of $(1.33), far worse than the estimated $(0.30).
RevenueRevenue was $2.6 million, significantly missing both internal and consensus estimates.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBY FAQ
What was Novabay Pharmaceuticals’s price range in the past 12 months?
Novabay Pharmaceuticals lowest stock price was $1.85 and its highest was $44.80 in the past 12 months.
What is Novabay Pharmaceuticals’s market cap?
Currently, no data Available
When is Novabay Pharmaceuticals’s upcoming earnings report date?
Novabay Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Novabay Pharmaceuticals’s earnings last quarter?
Novabay Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$5.25 earnings per share for the quarter, the consensus estimate of -$5.25 by $0.
Is Novabay Pharmaceuticals overvalued?
According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Overvalued.
Does Novabay Pharmaceuticals pay dividends?
Novabay Pharmaceuticals does not currently pay dividends.
What is Novabay Pharmaceuticals’s EPS estimate?
Novabay Pharmaceuticals’s EPS estimate is -$1.23.
How many shares outstanding does Novabay Pharmaceuticals have?
Novabay Pharmaceuticals has 1,080,897 shares outstanding.
What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?
Novabay Pharmaceuticals reported an EPS of -$5.25 in its last earnings report, expectations of -$5.25. Following the earnings report the stock price went down -9.936%.
Which hedge fund is a major shareholder of Novabay Pharmaceuticals?
Currently, no hedge funds are holding shares in NBY
---
NovaBay Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.68 (-16.00% Downside)
$1.68 (-16.00% Downside)
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.35%
12-Months-Change
Fundamentals
Return on Equity
-242.89%
Trailing 12-Months
Asset Growth
-63.87%
Trailing 12-Months
Company Description
Novabay Pharmaceuticals
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. Its products include Avenova, NeutroPhase, and CelleRx. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
---
NBY Earnings Call
Q1 2024
0:00 / 0:00
---
NBY Stock 12 Month Forecast
Average Price Target
$1.68
▼(-16.00% Downside)
Technical Analysis
Best Analysts Covering NBY
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-64.12%
reiterated a buy rating 2 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -64.12% per trade.
---